These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 1554398)

  • 1. Increased oxidizability of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to glycation.
    Babiy AV; Gebicki JM; Sullivan DR; Willey K
    Biochem Pharmacol; 1992 Mar; 43(5):995-1000. PubMed ID: 1554398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of vitamin E, probucol, and lovastatin on oxidative status and aortic fatty lesions in hyperlipidemic-diabetic hamsters.
    El-Swefy S; Schaefer EJ; Seman LJ; van Dongen D; Sevanian A; Smith DE; Ordovas JM; El-Sweidy M; Meydani M
    Atherosclerosis; 2000 Apr; 149(2):277-86. PubMed ID: 10729377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Requirement for, promotion, or inhibition by alpha-tocopherol of radical-induced initiation of plasma lipoprotein lipid peroxidation.
    Neuzil J; Thomas SR; Stocker R
    Free Radic Biol Med; 1997; 22(1-2):57-71. PubMed ID: 8958130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans.
    Reaven PD; Parthasarathy S; Beltz WF; Witztum JL
    Arterioscler Thromb; 1992 Mar; 12(3):318-24. PubMed ID: 1547191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysophosphatidylcholine molecular species in low density lipoprotein and high density lipoprotein in alloxan-induced diabetic rats: effect of probucol.
    Shi A; Yoshinari M; Iino K; Wakisaka M; Iwase M; Fujishima M
    Exp Clin Endocrinol Diabetes; 1999; 107(6):337-42. PubMed ID: 10543409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differing effects of probucol and vitamin E on the oxidation of lipoproteins, ceroid accumulation and protein uptake by macrophages.
    Hunt JV; Bottoms MA; Taylor SE; Lyell V; Mitchinson MJ
    Free Radic Res; 1994 Mar; 20(3):189-201. PubMed ID: 8019642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of low- and high-density lipoproteins from diabetic subjects to in vitro oxidative modification.
    Julier K; Mackness MI; Dean JD; Durrington PN
    Diabet Med; 1999 May; 16(5):415-23. PubMed ID: 10342342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole plasma oxidation assay as a measure of lipoprotein oxidizability.
    Kontush A; Spranger T; Reich A; Djahansouzi S; Karten B; Braesen JH; Finckh B; Kohlschütter A; Beisiegel U
    Biofactors; 1997; 6(2):99-109. PubMed ID: 9259991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus.
    Fuller CJ; Chandalia M; Garg A; Grundy SM; Jialal I
    Am J Clin Nutr; 1996 May; 63(5):753-9. PubMed ID: 8615360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consequences of treatment with dexamethasone in rats on the susceptibility of total plasma and isolated lipoprotein fractions to copper oxidation.
    Belkebir-Mesbah D; Bonnefont-Rousselot D; Frey-Fressart V; Moinard C; Delattre J; Vasson MP
    Endocrine; 1999 Jun; 10(3):233-42. PubMed ID: 10484287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of in-vivo supplementation with low-dose vitamin E on susceptibility of low-density lipoprotein and high-density lipoprotein to oxidative modification.
    Suzukawa M; Ishikawa T; Yoshida H; Nakamura H
    J Am Coll Nutr; 1995 Feb; 14(1):46-52. PubMed ID: 7706609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
    Lankin VZ; Tikhaze AK; Kukharchuk VV; Konovalova GG; Pisarenko OI; Kaminnyi AI; Shumaev KB; Belenkov YN
    Mol Cell Biochem; 2003 Jul; 249(1-2):129-40. PubMed ID: 12956408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperketonemia (acetoacetate) increases the oxidizability of LDL + VLDL in Type-I diabetic patients.
    Jain SK; McVie R; Jaramillo JJ; Chen Y
    Free Radic Biol Med; 1998 Jan; 24(1):175-81. PubMed ID: 9436628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased oxidizability of plasma low density lipoprotein from patients with coronary artery disease.
    Chiu HC; Jeng JR; Shieh SM
    Biochim Biophys Acta; 1994 Jan; 1225(2):200-8. PubMed ID: 8280789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin E content and low density lipoprotein oxidizability induced by free radicals.
    Babiy AV; Gebicki JM; Sullivan DR
    Atherosclerosis; 1990 Apr; 81(3):175-82. PubMed ID: 2350369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship of chemical modification of membrane proteins and plasma lipoproteins to reduced membrane fluidity of erythrocytes from diabetic subjects.
    Watala C; Winocour PD
    Eur J Clin Chem Clin Biochem; 1992 Sep; 30(9):513-9. PubMed ID: 1457612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity.
    Morel DW; Chisolm GM
    J Lipid Res; 1989 Dec; 30(12):1827-34. PubMed ID: 2621411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased susceptibility to lipid oxidation of low-density lipoproteins and erythrocyte membranes from diabetic patients.
    Rabini RA; Fumelli P; Galassi R; Dousset N; Taus M; Ferretti G; Mazzanti L; Curatola G; Solera ML; Valdiguié P
    Metabolism; 1994 Dec; 43(12):1470-4. PubMed ID: 7990698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of probucol on lipoprotein protein kinetics.
    Nestel PJ
    Artery; 1982; 10(2):95-8. PubMed ID: 7092582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of oxidized lipoproteins in the pathogenesis of atherosclerosis.
    Kita T; Yokode M; Ishii K; Kume N; Nagano Y; Arai H; Otani H; Ueda Y; Hara S
    Clin Exp Pharmacol Physiol Suppl; 1992; 20():37-42. PubMed ID: 1446408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.